Showing 281 - 300 results of 6,944 for search 'significantly ((((we decrease) OR (nn decrease))) OR (((teer decrease) OR (greater decrease))))', query time: 0.42s Refine Results
  1. 281

    Top-level overview for ADHD classification study. by Ahmed Akib Jawad Karim (20427740)

    Published 2025
    “…Referring to LastBERT, a customized student BERT model, we significantly lowered model parameters from 110 million BERT base to 29 million-resulting in a model approximately 73.64% smaller. …”
  2. 282

    NIE ELISA results. by Jannet A. Tobon Ramos (20855642)

    Published 2025
    “…Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (<i>p</i><0.001, both comparisons). …”
  3. 283

    Kato Katz and PCR database 12 months collection. by Jannet A. Tobon Ramos (20855642)

    Published 2025
    “…Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (<i>p</i><0.001, both comparisons). …”
  4. 284

    Master database baseline, 4 weeks and 1 year. by Jannet A. Tobon Ramos (20855642)

    Published 2025
    “…Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (<i>p</i><0.001, both comparisons). …”
  5. 285
  6. 286
  7. 287

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
  8. 288
  9. 289
  10. 290

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  11. 291

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  12. 292

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  13. 293
  14. 294
  15. 295
  16. 296
  17. 297
  18. 298
  19. 299
  20. 300